Project Grant R43AR074351

This $394,482 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop and validate demineralized bone paper (DBP)-based human bone metabolic and senolytic assays to support bone-targeting drug discovery and treatment regimens. The proposed DBP-based models will provide predictive bone assays for screening new anti-bone-aging drugs and improving treatment strategies for cancer survivors at risk of...

This $313,000 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research by Emory University to establish phosphorylated WNT5A produced by osteoclasts as a potential anabolic bone drug. The research aims to determine how osteoclast-derived phospho-WNT5A can enhance bone formation in vivo and elucidate the cellular and molecular mechanisms by...

This Project Grant award of $1,175,680.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research to assess the potential benefits of combined anabolic therapy versus a single-drug approach for treating postmenopausal osteoporosis. The awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will conduct a comparative study...

This Project Grant award of $1,722,291.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will fund the development of novel metformin-releasing injectable scaffolds to enhance dental pulp stem cell-based regeneration of critical-sized craniofacial bone defects. The University of Maryland, Baltimore is the prime awardee. The key objectives are to: (1) demonstrate that metformin's osteogenic and...

This federal Project Grant award of $465,663 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to optimize the bone surface targeting of therapeutic antibodies for treating osteoporosis. The key objectives are to: 1) Optimize the pharmacokinetics and pharmacodynamics of an anti-sclerostin antibody in healthy and osteoporosis model mice, and conduct a...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) is supporting the development of an optimized, off-the-shelf alternative to autologous fat grafting for soft tissue repair. The $293,983 award to Insoma Bio, Inc., a biotechnology company in Durham, North Carolina, will evaluate the combination of Insoma Bio's Fractomer tissue repair matrix and the Renuva adipose allograft material from MTF...

This Project Grant award of $312,871, awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports the development of a novel pro-angiogenic bone coating hydrogel (ABC hydrogel) for the treatment of osteonecrosis. The key objectives are to: 1) determine the physical, chemical, and cytocompatibility properties of the ABC hydrogel; 2) optimize the pro-angiogenic...

This Project Grant award from the National Institute on Aging (NIA), under the Aging Research (CFDA 93.866) Federal Grant Program, supports research into the mechanisms of inflammatory osteoblastogenesis and bone formation. The $688,634 award to The Hospital For Special Surgery Fund, Inc. (doing business as HSS Foundation) will fund a 5-year investigation into how the constitutive type-I interferon response in osteoblasts suppresses bone formation, and how this is influenced by aging and...

This Project Grant award of $1,857,842 from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will fund a 12-month randomized controlled trial. The trial will test the hypothesis that administering the drug romosozumab, followed by a single dose of zoledronic acid, to amenorrheic adolescents and young adults with functional hypothalamic amenorrhea (FHA) can improve their bone mineral...

The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), awarded a $613,736 Project Grant to Cayman Chemical Co Inc. to develop novel osteogenic small-molecule pharmacotherapies for local delivery that stimulate alveolar bone regeneration. The goal is to address the clinical need for improved treatments for periodontitis-related bone resorption, especially in aging populations. The project leverages Cayman...